Evidence Level
Coenzyme Q10 (CoQ10) is a vital nutrient with substantial evidence supporting its role in cardiovascular health and beyond. The Q-SYMBIO trial demonstrated that CoQ10 supplementation significantly reduces mortality and morbidity in patients with chronic heart failure, emphasizing its importance in mitochondrial energy production (Mortensen et al., 2014). Additionally, CoQ10 has been shown to alleviate statin-induced myopathy, as supported by a systematic review of five studies involving 800 participants (Ahmad et al., 2024).
Recent research highlights CoQ10's anti-inflammatory and endothelial protective effects. A 2023 meta-analysis of 31 RCTs with 1517 participants found that daily doses of 300-400 mg significantly reduced inflammatory biomarkers such as CRP, IL-6, and TNF-α (Hou et al., 2023). Furthermore, a systematic review of 12 studies involving 489 subjects demonstrated that CoQ10 supplementation improves vascular endothelial function through dose-dependent enhancements in flow-mediated dilation (Daei et al., 2024).
CoQ10's benefits are particularly notable in aging populations and those with mitochondrial dysfunction, as endogenous levels decline after age 20. The ubiquinol form is preferred due to its superior bioavailability compared to ubiquinone (Caso et al., 2007). These findings collectively establish CoQ10 as a crucial supplement for mitigating oxidative stress, inflammation, and cardiovascular risk across diverse populations.